Sexually transmitted infections (STIs) are one of the world’s most serious and widespread public health challenges. More than 1 million STIs are acquired every day, according to the World Health Organization. In 2020 alone, an estimated 37.6 million people worldwide were living with HIV and 1.5 million individuals became newly infected.
A recently awarded grant will allow Connie Celum, a University of Washington professor of Global Health and Medicine, to evaluate whether doxycycline—an antibiotic commonly used to treat acne and Lyme disease—is safe and effective in reducing bacterial sexually transmitted infections. The study focuses on men who have sex with men (MSM) and transgender women (TGW) living with HIV and taking pre-exposure prophylaxis (PrEP), a daily pill used to prevent HIV.
By Melissa Matthews / Newsweek
You’ve likely never heard of, or been tested for it, but a sexually transmitted infection that’s fairly common could now be resistant to antibiotic medications. Mycoplasma genitalium, or MG, is not a new bacteria and was first identified in the 1980s. According to the Centers for Disease Control and Prevention, it is more common than gonorrhea and chlamydia, though it's not as easily recognized as the other two.